| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sabrina Chiloiro, Antonella Giampietro, Stefano Frara, Chiara Bima, Federico Donfrancesco, Cara Maya Fleseriu, Alfredo Pontecorvi, Andrea Giustina, Maria Fleseriu, Laura De Marinis, Antonio Bianch. Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. The Journal of clinical endocrinology and metabolism. vol 105. issue 3. 2020-11-09. PMID:31613969. |
in somatostatin receptor ligands (srl)-resistant patients, pegvisomant (pegv) and pasireotide lar (pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined. |
2020-11-09 |
2023-08-13 |
Not clear |
| Chengxian Yang, Ge Li, Shenzhong Jiang, Xinjie Bao, Renzhi Wan. Preoperative Somatostatin Analogues in Patients with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of Comparative Studies. Scientific reports. vol 9. issue 1. 2020-11-02. PMID:31575930. |
preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies. |
2020-11-02 |
2023-08-13 |
Not clear |
| Ming Shen, Meng Wang, Wenqiang He, Min He, Nidan Qiao, Zengyi Ma, Zhao Ye, Qilin Zhang, Yichao Zhang, Yeping Yang, Yanjiao Cai, Yakupujiang ABuDuoReYiMu, Yun Lu, Bin Lu, Xuefei Shou, Yongfei Wang, Hongying Ye, Yiming Li, Shiqi Li, Yao Zhao, Xiaoyun Cao, Zhaoyun Zhan. Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study. International journal of endocrinology. vol 2018. 2020-10-01. PMID:29853879. |
impact of long-acting somatostatin analogues on glucose metabolism in acromegaly: a hospital-based study. |
2020-10-01 |
2023-08-13 |
Not clear |
| Juan D Palacios, Ricardo J Komotar, Atil Y Karg. Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy. Case reports in endocrinology. vol 2018. 2020-10-01. PMID:30046497. |
clomiphene citrate (cc) has been reported as an effective add-on therapy to somatostatin analogs and dopamine agonists in patients with acromegaly accompanied by hypogonadism; its use as a single agent to treat acromegaly and associated hypogonadism following incomplete surgery has not been previously reported. |
2020-10-01 |
2023-08-13 |
Not clear |
| Daniele Cappellani, Claudio Urbani, Chiara Sardella, Ilaria Scattina, Giulia Marconcini, Isabella Lupi, Luca Manetti, Claudio Marcocci, Fausto Bogazz. Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinology, diabetes & metabolism. vol 2. issue 1. 2020-10-01. PMID:30815570. |
therapy with somatostatin analogues (ssas) may have deleterious effects on glucose metabolism in patients with acromegaly, often leading to the development of diabetes mellitus (dm). |
2020-10-01 |
2023-08-13 |
Not clear |
| Maryam Heidarpour, Davood Shafie, Ashraf Aminorroaya, Nizal Sarrafzadegan, Ziba Farajzadegan, Rasool Nouri, Arash Najimi, Christina Dimopolou, Gunter Stall. Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. vol 24. 2020-10-01. PMID:31143230. |
effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: a systematic review. |
2020-10-01 |
2023-08-13 |
Not clear |
| Maryam Heidarpour, Davood Shafie, Ashraf Aminorroaya, Nizal Sarrafzadegan, Ziba Farajzadegan, Rasool Nouri, Arash Najimi, Christina Dimopolou, Gunter Stall. Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. vol 24. 2020-10-01. PMID:31143230. |
there is a belief that in patients with acromegaly, first-generation somatostatin analogs (ssas) might improve cardiovascular (cv) structure and function. |
2020-10-01 |
2023-08-13 |
Not clear |
| Karim Gariani, Patrick Meyer, Jacques Philipp. Implications of Somatostatin Analogues in the Treatment of Acromegaly. European endocrinology. vol 9. issue 2. 2020-09-30. PMID:29922369. |
implications of somatostatin analogues in the treatment of acromegaly. |
2020-09-30 |
2023-08-13 |
Not clear |
| Ming Shen, Meng Wang, Wenqiang He, Min He, Nidan Qiao, Zengyi Ma, Zhao Ye, Qilin Zhang, Yichao Zhang, Yeping Yang, Yanjiao Cai, Yakupujiang ABuDuoReYiMu, Yun Lu, Bin Lu, Xuefei Shou, Yongfei Wang, Hongying Ye, Yiming Li, Shiqi Li, Yao Zhao, Xiaoyun Cao, Zhaoyun Zhan. Erratum to "Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study". International journal of endocrinology. vol 2019. 2020-09-30. PMID:30962806. |
erratum to "impact of long-acting somatostatin analogues on glucose metabolism in acromegaly: a hospital-based study". |
2020-09-30 |
2023-08-13 |
Not clear |
| Fabio Tortora, Alberto Negro, Ludovica F S Grasso, Annamaria Colao, Rosario Pivonello, Alessandra Splendiani, Luca Brunese, Ferdinando Caranc. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland surgery. vol 8. issue Suppl 3. 2020-09-30. PMID:31559182. |
previous data have demonstrated a correlation between t2-weighted tumor signal intensity and response to therapy with conventional somatostatin analogs (ssa) in patients with acromegaly. |
2020-09-30 |
2023-08-13 |
Not clear |
| Zaina Adnan, Ilan Shimo. PASIREOTIDE FOR A PATIENT WITH ACROMEGALY AND CHRONIC KIDNEY DISEASE ON HEMODIALYSIS. AACE clinical case reports. vol 5. issue 2. 2020-09-30. PMID:31967012. |
we present a case report of a patient with acromegaly on chronic hemodialysis resistant to first-generation, long-acting somatostatin analogs with remarkable response to pasireotide long-acting release (pas-lar). |
2020-09-30 |
2023-08-13 |
Not clear |
| Cristina Alvarez-Escola, Jersy Cardenas-Sala. Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues. Endocrinology, diabetes & metabolism case reports. vol 2016. 2020-09-29. PMID:27933171. |
active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues. |
2020-09-29 |
2023-08-13 |
Not clear |
| Cristina Alvarez-Escola, Jersy Cardenas-Sala. Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues. Endocrinology, diabetes & metabolism case reports. vol 2016. 2020-09-29. PMID:27933171. |
in patients with active acromegaly after pituitary surgery, somatostatin analogues are effective in controlling the disease and can even be curative in some cases. |
2020-09-29 |
2023-08-13 |
Not clear |
| Athanasios Fountas, Shu Teng Chai, John Ayuk, Neil Gittoes, Swarupsinh Chavda, Niki Karavitak. A rare challenging case of co-existent craniopharyngioma, acromegaly and squamous cell lung cancer. Endocrinology, diabetes & metabolism case reports. vol 2018. 2020-09-29. PMID:29623208. |
treatment with long-acting somatostatin analogue was initiated leading to biochemical control of the acromegaly. |
2020-09-29 |
2023-08-13 |
Not clear |
| Melissa Rodriguez, Jeffrey A Frost, Agnes Schonbrun. Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells. Journal of the Endocrine Society. vol 2. issue 7. 2020-09-29. PMID:30151433. |
som230 is a somatostatin analogue that targets multiple sstrs and was recently approved for patients with treatment-resistant acromegaly. |
2020-09-29 |
2023-08-13 |
rat |
| Sanne E Franck, Aart Jan van der Lely, Sebastian Negger. Extra-hepatic Acromegaly. European endocrinology. vol 9. issue 1. 2020-09-29. PMID:30349613. |
after the introduction of somatostatin analogs (la-smsa) and the growth hormone (gh) receptor antagonist, pegvisomant (peg-v) normal serum insulin-like growth factor-1 (igf-1) concentrations in virtually every patients with acromegaly is possible. |
2020-09-29 |
2023-08-13 |
Not clear |
| Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Becker. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocrine connections. vol 8. issue 4. 2020-09-28. PMID:30851160. |
aip-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide lar in two patients. |
2020-09-28 |
2023-08-13 |
Not clear |
| Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, Albert Becker. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocrine connections. vol 8. issue 4. 2020-09-28. PMID:30851160. |
aryl hydrocarbon receptor interacting protein (aip) mutations are associated with an aggressive, inheritable form of acromegaly that responds poorly to sst2-specific somatostatin analogs (ssa). |
2020-09-28 |
2023-08-13 |
Not clear |
| Anne Marie Hannon, Isolda Frizelle, George Kaar, Steven J Hunter, Mark Sherlock, Christopher J Thompson, Domhnall J O'Hallora. Octreotide use for rescue of vision in a pregnant patient with acromegaly. Endocrinology, diabetes & metabolism case reports. vol 2019. 2020-09-28. PMID:31117051. |
in conclusion, our case describes a first presentation of acromegaly in pregnancy and rescue of visual field loss with somatostatin analogue therapy. |
2020-09-28 |
2023-08-13 |
Not clear |
| Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes, Antoine Tabari. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocrine connections. vol 8. issue 10. 2020-09-28. PMID:31518993. |
little data are available regarding the safety and efficacy of switching to pasireotide-lar monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gsrl) who require combination treatment with cabergoline or pegvisomant. |
2020-09-28 |
2023-08-13 |
Not clear |